Three‐year follow‐up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non‐small cell lung cancer: Pooled analysis of ONO‐4538‐05 and ONO‐4538‐06 studies

BACKGROUND: Nivolumab is a programmed cell death 1 (PD‐1) receptor inhibitor antibody that enhances immune system antitumor activity. It is associated with longer overall survival (OS) than the standard treatment of docetaxel in patients with previously treated advanced squamous (SQ) and non‐squamou...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Med
Glavni autori: Horinouchi, Hidehito, Nishio, Makoto, Hida, Toyoaki, Nakagawa, Kazuhiko, Sakai, Hiroshi, Nogami, Naoyuki, Atagi, Shinji, Takahashi, Toshiaki, Saka, Hideo, Takenoyama, Mitsuhiro, Katakami, Nobuyuki, Tanaka, Hiroshi, Takeda, Koji, Satouchi, Miyako, Isobe, Hiroshi, Maemondo, Makoto, Goto, Koichi, Hirashima, Tomonori, Minato, Koichi, Sumiyoshi, Naoki, Tamura, Tomohide
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2019
Teme:
Clinical Cancer Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6718542/
https://ncbi.nlm.nih.gov/pubmed/31353840
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2411
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items